CellVoyant
Saad M. currently serves as the ML/AI Science Lead at CellVoyant since July 2022 and has been a Researcher at the University of Bristol since September 2020, focusing on applying machine learning to biological questions related to stem cell data. Prior experience includes a Research Fellow position at the University of Warwick - WMG, where the development of deep reinforcement learning algorithms took place, and roles as a Postdoctoral Researcher and Tutor at Bournemouth University, concentrating on pattern mining from large-scale data for energy management. Saad M. also contributed as a Postdoctoral Researcher at the Energy Technologies Institute and was involved in PhD research related to active learning and data streams at IMT, complemented by engineering training at Heudiasyc Laboratory and Cimenterie Nationale. The educational background includes a Master's degree in Electricity and Electronics from Lebanese University, completed in 2013.
This person is not in any teams
CellVoyant
CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol. We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world. Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.